Updates are available Correction dated 2024-03-06
Click to view Correction: https://doi.org/10.1038/s41591-024-02898-8
-
Authors
Verschoor, Yara L. http://orcid.org/0009-0005-7217-1460
van de Haar, Joris http://orcid.org/0000-0001-5899-3971
van den Berg, José G.
van Sandick, Johanna W.
Kodach, Liudmila L.
van Dieren, Jolanda M. http://orcid.org/0000-0003-3958-4990
Balduzzi, Sara http://orcid.org/0000-0003-1205-1895
Grootscholten, Cecile
IJsselsteijn, Marieke E.
Veenhof, Alexander A. F. A.
Hartemink, Koen J.
Vollebergh, Marieke A.
Jurdi, Adham http://orcid.org/0000-0002-2985-3053
Sharma, Shruti
Spickard, Erik http://orcid.org/0000-0002-5024-3559
Owers, Emilia C.
Bartels-Rutten, Annemarieke
den Hartog, Peggy
de Miranda, Noel F. C. C. http://orcid.org/0000-0001-6122-1024
van Leerdam, Monique E. http://orcid.org/0000-0002-5719-3208
Haanen, John B. A. G. http://orcid.org/0000-0001-5884-7704
Schumacher, Ton N. http://orcid.org/0000-0003-0517-8804
Voest, Emile E. http://orcid.org/0000-0001-8249-9586
Chalabi, Myriam http://orcid.org/0000-0002-8607-6174
-
Funding
Funding for this research was provided by:
Roche
- License Information
-
More Information
Article History
Received: 12 May 2023
Accepted: 7 December 2023
First Online: 8 January 2024
Change Date: 6 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-02898-8
Competing interests
: Y.L.V., J.v.d.H., J.G.v.d.B., J.W.v.S., J.M.v.D., S.B., C.G., M.E.I., A.A.F.A.V., K.J.H., M.A.V., E.C.O., A.B-R., P.d.H., N.F.C.C.d.M. and M.E.v.L. declare no competing interests. L.L.K. reports research funding to the institute from BMS outside the submitted work. A.J., S.S. and E.S. are full-time employees of Natera, Inc. with stocks and/or stock options to own in the company. J.B.A.G.H. has (had) advisory roles with Achilles Therapeutics, AstraZeneca, Bayer, Bristol Myers Squibb, BioNTech, GSK, Immunocore, Iovance Bio, Instil Bio, Ipsen, MSD, Merck Serono, Molecular Partners, Novartis, Neogene Therapeutics, Pfizer, Roche/Genentech, Sanofi, Scenic Bio, T-Knife and Third Rock Ventures and has received research grants not related to this paper from Amgen, Bristol Myers Squibb, MSD, BioNTech, Novartis and Sastra Cell Therapy. All grants were paid to the institutions. T.N.S. is advisor for Allogene Therapeutics, Asher Bio, Celsius, Merus, Neogene Therapeutics and Scenic Biotech; is a stockholder in Allogene Therapeutics, Asher Bio, Cell Control, Celsius, Merus and Scenic Biotech; and is venture partner at Third Rock Ventures, all outside of the current work. E.E.V. reports research funding from BMS outside the current work. M.C. has (had) advisory roles for NUMAB, KINETA, BMS, MSD and Roche/Genentech and received research grants not related to this paper from BMS, MSD and Roche-Genentech. All grants were paid to the institutions.
